Nuvectis Pharma, Inc.(NVCT)Earnings, Financials & Key RatiosNuvectis Pharma, Inc. (NVCT) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on external financing to cover a $6.5 million quarterly cash burn and the absence of revenue streams present a substantial risk to long-term shareholder value.
Nuvectis Pharma, Inc. (NVCT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Nuvectis Pharma, Inc. (NVCT) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.26vs $0.30+13.3% | — |
| Q1 2026 | Feb 11, 2026 | $0.31vs $0.26-19.2% | — |
| Q4 2025 | Nov 4, 2025 | $0.44vs $0.24-83.3% | — |
| Q3 2025 | Aug 5, 2025 | $0.30vs $0.25-20.0% | — |
Recent stock market news and headlines for Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks Transcript
Nuvectis Pharma said on Monday it had licensed exclusive rights outside China to two experimental drugs from Haisco Pharmaceutical Group , targeting complement-mediated diseases and cancer to broaden its pipeline.
Fort Lee, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced a strategic portfolio expansion via a license agreement for exclusive ex-China rights with Haisco Pharmaceutical Group (“Haisco”) to two potentially best in-class clinical-stage compounds. Nuvectis will hold a conference call today at 8:30 AM ET to introduce its newly in-licensed products.
Key metrics vs top competitors for Nuvectis Pharma, Inc. (NVCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.19 | $721.23M | -20.60 | — | — | -188.03% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $31.47 | $3.66B | -36.17 | 48.29% | -188.15% | -41.54% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $123.52 | $9.09B | -21.11 | — | — | -42.78% | — |
Nuvectis Pharma, Inc. (NVCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Nuvectis Pharma, Inc. (NVCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Feb 11, 2026·SEC
Nov 4, 2025·SEC
Get notified when NVCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nuvectis Pharma, Inc. (NVCT) stock FAQ — growth, dividends, profitability & financials explained
Nuvectis Pharma, Inc. (NVCT) reported a net loss of $27.2M for fiscal year 2025.
Nuvectis Pharma, Inc. (NVCT) has a return on equity (ROE) of -188.0%. Negative ROE indicates the company is unprofitable.
Nuvectis Pharma, Inc. (NVCT) had negative free cash flow of $18.3M in fiscal year 2025, likely due to heavy capital investments.
